Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 4
1997 1
1998 4
1999 1
2000 8
2001 8
2002 16
2003 19
2004 25
2005 32
2006 28
2007 31
2008 34
2009 27
2010 31
2011 29
2012 26
2013 32
2014 27
2015 41
2016 52
2017 33
2018 31
2019 43
2020 28
2021 42
2022 19
2023 12
2024 8

Text availability

Article attribute

Article type

Publication date

PubMed (MeSH Keyword) for id: 5352062

611 results

Results by year

Filters applied: . Clear all
Page 1
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas RO, Ysebaert L, Damaj GL, Guidez S, Pica GM, Kim WS, Lim ST, Andre M, Gutiérrez N, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Tucci A, Fogarty P, Farhat H, Abraham J, Abarah W, Belmecheri F, Ribrag V, Delfau-Larue MH, Cottereau AS, Itti E, Li J, Delarue R, de Leval L, Morschhauser F, Bachy E. Camus V, et al. J Clin Oncol. 2024 May 10;42(14):1612-1618. doi: 10.1200/JCO.23.01687. Epub 2024 Feb 16. J Clin Oncol. 2024. PMID: 38364196 Clinical Trial.
Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination.
Duran-Castells C, Prats A, Oriol-Tordera B, Llano A, Galvez C, Martinez-Picado J, Ballana E, Garcia-Vidal E, Clotet B, Muñoz-Moreno JA, Hanke T, Moltó J, Mothe B, Brander C, Ruiz-Riol M. Duran-Castells C, et al. EBioMedicine. 2023 Sep;95:104732. doi: 10.1016/j.ebiom.2023.104732. Epub 2023 Jul 26. EBioMedicine. 2023. PMID: 37506557 Free PMC article. Clinical Trial.
Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Iyer SP, Huen A, Ai WZ, Jagadeesh D, Lechowicz MJ, Okada C, Feldman TA, Ghione P, Alderuccio JP, Champion R, Kim SH, Mohrbacher A, Routhu KV, Barde P, Nair AM, Haverkos BM. Iyer SP, et al. Haematologica. 2024 Jan 1;109(1):209-219. doi: 10.3324/haematol.2022.281875. Haematologica. 2024. PMID: 37439343 Free PMC article. Clinical Trial.
611 results